ARCHIVES

AstraZeneca To Pay $335M In Illegal Pricing Penalties.

This article is from The Cancer Letter archive.

Vol. 29 No. 26 | June 27, 2003

Download PDF Visit The Full Archive

Related Articles

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

December 31, 2010

Phase III Trial Finds Cabazitaxel Increases Survival Of Advanced Prostate Cancer

March 26, 2010

Cancer Program Critics Called “Irresponsible,” Demagogues”

March 21, 1975

New Carfilzomib Combination Produces Near Remissions

June 29, 2012

BMS Settles Charges Of Obstructing Generics

March 14, 2003

New NIH Grant Program or Young Investigators

October 8, 2010